Nature Reviews Clinical Oncology
Vol. 23, Issue 5
Issue 5
2026
10
Articles
Articles in this Issue
In what clinical settings are the MASAI trial results applicable?
Karla Kerlikowske, Kathryn P. Lowry, Diana L. Miglioretti
May 01, 2026
pp. 319-320
10.1038/s41571-026-01143-0
Author Correction: Innovative approaches for lung cancer screening and interception
Jianjun Zhang, Matthew D. Park, Tej Pandya et al.
May 01, 2026
pp. 390-390
10.1038/s41571-026-01140-3
The changing landscape of oncology clinical trials in Latin America
Andreia Cristina de Melo
May 01, 2026
pp. 317-318
10.1038/s41571-026-01137-y
Lisocabtagene maraleucel has high efficacy in R/R MZL
David Killock
May 01, 2026
pp. 322-322
10.1038/s41571-026-01138-x
Enfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer
Peter Sidaway
May 01, 2026
pp. 321-321
10.1038/s41571-026-01139-w
Innovative approaches for lung cancer screening and interception
Jianjun Zhang, Matthew D. Park, Tej Pandya et al.
May 01, 2026
pp. 374-389
10.1038/s41571-026-01131-4
Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling
Giulia Martini, Stefania Napolitano, Davide Ciardiello et al.
May 01, 2026
pp. 356-373
10.1038/s41571-026-01126-1
Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours
Diana Romero
May 01, 2026
pp. 321-321
10.1038/s41571-026-01136-z
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization
Douglas B. Johnson, Amin H. Nassar, Ayesha Aijaz et al.
May 01, 2026
pp. 341-355
10.1038/s41571-026-01123-4
Engineering platelets as cancer therapeutics
Yu Chen, Tyler Wolter, Zhen Gu et al.
May 01, 2026
pp. 323-340
10.1038/s41571-026-01122-5
All Issues
Journal Info
Publisher
Springer Science and Business Media LLC
ISSN
1759-4774
E-ISSN
1759-4782
Subject
Medicine
Language
English